Unknown

Dataset Information

0

Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.


ABSTRACT: The objective of this study was to determine the extent to which the CYP2C8*3 allele influences pharmacokinetic variability in the drug-drug interaction between gemfibrozil (CYP2C8 inhibitor) and pioglitazone (CYP2C8 substrate).In this randomized, two phase crossover study, 30 healthy Caucasian subjects were enrolled based on CYP2C8*3 genotype (n = 15, CYP2C8*1/*1; n = 15, CYP2C8*3 carriers). Subjects received a single 15 mg dose of pioglitazone or gemfibrozil 600 mg every 12 h for 4 days with a single 15 mg dose of pioglitazone administered on the morning of day 3. A 48 h pharmacokinetic study followed each pioglitazone dose and the study phases were separated by a 14 day washout period.Gemfibrozil significantly increased mean pioglitazone AUC(0,?) by 4.3-fold (P < 0.001) and there was interindividual variability in the magnitude of this interaction (range, 1.8- to 12.1-fold). When pioglitazone was administered alone, the mean AUC(0,?) was 29.7% lower (P = 0.01) in CYP2C8*3 carriers compared with CYP2C8*1 homozygotes. The relative change in pioglitazone plasma exposure following gemfibrozil administration was significantly influenced by CYP2C8 genotype. Specifically, CYP2C8*3 carriers had a 5.2-fold mean increase in pioglitazone AUC(0,?) compared with a 3.3-fold mean increase in CYP2C8*1 homozygotes (P = 0.02).CYP2C8*3 is associated with decreased pioglitazone plasma exposure in vivo and significantly influences the pharmacokinetic magnitude of the gemfibrozil-pioglitazone drug-drug interaction. Additional studies are needed to evaluate the impact of CYP2C8 genetics on the pharmacokinetics of other CYP2C8-mediated drug-drug interactions.

SUBMITTER: Aquilante CL 

PROVIDER: S-EPMC3555061 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Aim</h4>The objective of this study was to determine the extent to which the CYP2C8*3 allele influences pharmacokinetic variability in the drug-drug interaction between gemfibrozil (CYP2C8 inhibitor) and pioglitazone (CYP2C8 substrate).<h4>Methods</h4>In this randomized, two phase crossover study, 30 healthy Caucasian subjects were enrolled based on CYP2C8*3 genotype (n = 15, CYP2C8*1/*1; n = 15, CYP2C8*3 carriers). Subjects received a single 15 mg dose of pioglitazone or gemfibrozil 600 mg  ...[more]

Similar Datasets

| S-EPMC6885506 | biostudies-literature
| S-EPMC9496539 | biostudies-literature
| S-EPMC3760990 | biostudies-literature
| S-EPMC7696733 | biostudies-literature
| S-EPMC7997453 | biostudies-literature
| S-EPMC7591087 | biostudies-literature
| S-EPMC8467590 | biostudies-literature
| PRJEB31589 | ENA
| S-EPMC7720126 | biostudies-literature
| S-EPMC9145019 | biostudies-literature